UNSPSC 51191543: Cyclopenthiazide

This classification denotes a thiazide diuretic with the molecular formula C13H18ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VX4S2N85F5, chemically known as 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-2h-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as cyclopenthiazide, which bears US NIH Compound Identifier 2904. European Medicines Agency schedules Cyclopenthiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06857MIG.

UNSPSC 51191543 Cyclopenthiazide is a Commodity code, but the recent state and local opportunities tagged under it involve water treatment chemicals, parenteral medical products, and industrial valve systems—none of which are cyclopenthiazide, a diuretic pharmaceutical. The code shows little relevant recent activity; the three posted solicitations represent a clear mismatch between the code's nominal pharmaceutical scope and the actual procurement tagged to it.

The three recent opportunities span disparate issuing bodies and geographies. Broward County, Florida issued an RFI (September 18, 2026, responses due September 29, 2026) for DeZurik/APCO valves, parts, and repair services for wastewater treatment compliance. The Washington State Department of Corrections issued an RFQQ (September 8, 2026, responses due October 7, 2026) for parenteral products and services—parenteral nutrition solutions, intravenous solutions, and controlled substances—to supply eight correctional facilities across Washington state with pre-bid conference on September 23, 2026; the DOC intends to award up to three bidders per region and offers state set-aside targets for small businesses (25%), minority-owned (10%), women-owned (6%), and veteran-owned (5%) firms. The City of Meriden, Connecticut issued an IFB (August 14, 2026, bids due July 29, 2026) for sodium bisulfite chemical supply for its Water Pollution Control Facility. The geographic spread covers Florida, Washington, and Connecticut, with no pattern suggesting where cyclopenthiazide procurement, if any exists in state and local markets, actually occurs. Vendors should verify whether this code assignment reflects a data-entry error or a jurisdictional reclassification that has not yet aligned with actual sourcing intent.